Market Performance of Acadia (ACAD) and Peer Comparisons
Acadia (ACAD) traded down by 2.86 % during the 24‑hour period that concluded at 11:00 AM Central Europe on Monday, 26 November 2026. At the close, a single share was available for approximately USD 19.73 on major exchanges. The company’s share supply totals 172.3 million, while its market capitalisation stands at USD 3.4 billion. In the last 24 hours, roughly USD 21 million of Acadia shares changed hands.
Over the past month, Acadia’s shares have fallen by 11.05 %. Its simple moving average over the last 200 trading days is USD 23.84. The highest price the stock has reached in the past 52 weeks was USD 30.96, recorded on 19 August 2026; the 52‑week low was USD 18.39, seen on 13 October 2026.
Peer Performance Snapshot (Last 24 Hours)
| Stock | % Change | Current Price | Market Cap | P/E or PE Ratio |
|---|---|---|---|---|
| Belden (BDC) | +0.67 % | USD 104.15 | USD 4.1 billion | 17.07 |
| Tutor Perini (TPC) | –0.03 % | USD 76.86 | USD 4.0 billion | 33.12 |
| Telephone & Data (TDS) | +1.58 % | USD 35.33 | USD 4.1 billion | 9.02 |
| Adaptive Biotechnologies (ADPT) | +4.51 % | USD 25.51 | USD 4.1 billion | – |
| Indivior (INDV) | –2.43 % | USD 34.47 | USD 4.1 billion | 12.6 |
Acadia’s decline is consistent with its broader monthly downward trend, while some of its peers have seen modest gains or marginal declines. Notably, Adaptive Biotechnologies posted the most substantial gain among the group, rising over four percent, whereas Indivior and Acadia were the only stocks to fall.
Company Overview
ACADIA Pharmaceuticals Inc. is headquartered in San Diego, United States, and specializes in the discovery, development, and commercialization of small‑molecule drugs targeting central nervous system disorders. The company’s therapeutic pipeline focuses on conditions such as Parkinson’s disease, schizophrenia, neuropathic pain, and glaucoma. Acadia’s website, www.acadia‑pharm.com , provides detailed information on its research initiatives and product portfolio.
Listed on the Nasdaq exchange, Acadia conducted its initial public offering on 27 May 2004. Over the years, the company has built a reputation for developing innovative treatments aimed at alleviating complex neurological disorders, positioning itself as a notable player in the biopharmaceutical sector.